CYDY News and Press, CytoDyn Inc From 08/06/21

CytoDyn (OTCQB:CYDY) has filed a lawsuit against a shareholder activist group led by Paul Rosenbaum and Bruce Patterson, accusing them of misleading shareholders and waging an unlawful proxy contest. The lawsuit was filed in the United States District Court for the District of Delaware. "We a...

Suit Details Unlawful Attempts to Solicit Votes on Part of the Activist Group CytoDyn is Acting to Protect All Shareholders and Prevent Activist Group from Continuing to Violate Federal Securities Laws CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the ȁ...

CytoDyn (OTCQB:CYDY) announces that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the clinical trial protocol to commence patient enrollment in the company's CD17 trial of leronlimab for severe COVID-19 patients. The la...

Expects to Conduct Interim Analysis After Completion of 40% of the Enrollment The Academic Research Organization Albert Einstein Israelite Hospital in Brazil will Conduct the Trial CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnolog...

Nomination Notice Letter Contains Over 50 Significant Deficiencies and Fails to Meet Basic Requirements of CytoDyn’s Advance Notice Bylaw Myriad Omissions and Misstatements by the Rosenbaum/Patterson Group Raise Serious Questions About the Group’s Motives, Fundin...

FangXiaNuo/E+ via Getty Images A group of activist investors led by Paul Rosenbaum is pushing for a slate of new board member at CytoDyn (CYDY), citing poor stewardship by current management of the company's lead asset, leronlimab. Last week, Rosenbaum, along with Jeffrey Beaty and Arthur Wil...

CytoDyn (CYDY) will host an investment community webcast on Thursday, July 22, 2021 at 4:00 pm ET. Management will provide a full discussion of the results from the recently reported data from the mTNBC trials, along with updates on cancer, COVID-19, and NASH trials, and the status of the res...

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today N...

CytoDyn (CYDY) announces strong preliminary results from its Phase 1b/2 trials and compassionate use with a total of 30 metastatic triple-negative breast cancer (mTNBC) patients, treated with leronlimab in combination with carboplatin. Key findings from the interim 12-month analysis include:7...

VANCOUVER, Washington, July 19, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today strong preliminary resul...